# A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

> **NCT01461928** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 692 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Chemotherapy (Induction Period)
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01461928
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-20
- **Primary completion:** 2018-06-02
- **Final completion:** 2018-06-02
- **Target enrollment:** 692 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01461928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01461928, "A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01461928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*